Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
During acute coronary syndromes (ACS), the generation of inflammatory mediators negatively
influences arterial wall remodeling and the endothelium-dependent vasomotor function in the
coronary and systemic arterial systems. In fact, the intensity of the inflammatory
upregulation is strongly related to the incidence of recurrent coronary events. The
investigators previously demonstrated that high dose potent statins can rapidly reduce plasma
levels of cholesterol-rich lipoproteins and inflammatory activity in subjects during ACS. In
addition, such statin treatment attenuates the post-discharge endothelial dysfunction of
these patients. By inference, it is plausible to hypothesize that these beneficial effects
during ACS may be intensified by an additive lowering of plasma cholesterol through the
treatment with ezetimibe. So far, data is unavailable to verify this assumption. In parallel,
data from animal models have suggested that both statins and ezetimibe may reduce insulin
sensitivity by their effect on cholesterol content and, by this way, on insulin signaling in
liver cells. In this context, the present study aims to investigate the role of the addition
of ezetimibe upon statin treatment on stress-induced insulin resistance and on the
time-course of the inflammatory response during the acute phase of myocardial infarction and
its late effect on endothelium-dependent arterial dilation.
Phase:
Phase 4
Details
Lead Sponsor:
Brasilia Heart Study Group
Treatments:
Ezetimibe Ezetimibe, Simvastatin Drug Combination Simvastatin